FDA Approves Avastin To Treat Brain Cancer
SOUTH SAN FRANCISCO, Calif. (AP) ¿ The Food and Drug Administration granted accelerated approval to Roche's cancer drug Avastin as a treatment for glioblastoma, a type of brain cancer, Genentech Inc. said Wednesday.
Avastin was developed by Genentech and sold through a partnership with Roche. Switzerland-based Roche agreed to buy Genentech in March.
The FDA sped up its review process because it has been more than 10 years since a new treatment for glioblastoma was approved, according to Genentech. The approval is based on the drug's ability to achieve a partial or complete response in clinical trials. Genentech said there is currently no data showing the drug reduces symptoms or improves survival.
The company is also planning a late stage trial of Avastin as a treatment for newly diagnosed glioblastoma. The company said about 10,000 people in the U.S. have glioblastoma, and tumors usually come back after initial treatment.Avastin is approved a treatment for various forms of colon, breast and lung cancers. Last month, the company said the drug failed to stop early stage colon cancer.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV